BioTime (NYSEAMERICAN:BTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Friday.

According to Zacks, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. “

Separately, BidaskClub raised shares of BioTime from a “sell” rating to a “hold” rating in a research report on Thursday, September 28th. Three investment analysts have rated the stock with a sell rating and two have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $5.08.

Shares of BioTime (BTX) traded up $0.02 during mid-day trading on Friday, reaching $2.70. 212,300 shares of the company were exchanged, compared to its average volume of 579,463. BioTime has a fifty-two week low of $2.10 and a fifty-two week high of $3.62. The company has a market capitalization of $318.43, a price-to-earnings ratio of 6.28 and a beta of 2.03.

Several institutional investors and hedge funds have recently bought and sold shares of BTX. GSA Capital Partners LLP lifted its position in BioTime by 124.1% during the 3rd quarter. GSA Capital Partners LLP now owns 174,816 shares of the biotechnology company’s stock worth $496,000 after buying an additional 96,816 shares in the last quarter. Jane Street Group LLC lifted its position in BioTime by 95.6% during the 3rd quarter. Jane Street Group LLC now owns 44,548 shares of the biotechnology company’s stock worth $127,000 after buying an additional 21,778 shares in the last quarter. Broadwood Capital Inc. lifted its position in BioTime by 0.6% during the 3rd quarter. Broadwood Capital Inc. now owns 27,279,254 shares of the biotechnology company’s stock worth $77,473,000 after buying an additional 160,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in BioTime by 29.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 156,721 shares of the biotechnology company’s stock worth $445,000 after buying an additional 35,970 shares in the last quarter. Finally, Family Management Corp lifted its position in BioTime by 29.9% during the 3rd quarter. Family Management Corp now owns 182,350 shares of the biotechnology company’s stock worth $518,000 after buying an additional 41,979 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/12/biotime-btx-downgraded-by-zacks-investment-research.html.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.